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The endocannabinoid system (ECS) has gained much attention as a new potential 27 pharmacotherapeutic target in various neurodegenerative diseases, including Alzheimer's 28 disease (AD). However, the association between CB1 alterations and the development of AD 29 neuropathology is unclear and often contradictory. In this study, brain CB1 mRNA and CB1 30 protein levels were analysed in 3×Tg-AD mice and compared to wild-type littermates at 2, 6 31 and 12 months of age, using in-situ hybridization and immunohistochemistry, respectively. 32 Semiquantitative analysis of CB1 expression focused on the prefrontal cortex (PFC), 33 prelimbic cortex (PrL), dorsal hippocampus (DH), basolateral amygdala complex (BLA) and 34 ventral hippocampus (VH), all areas with high CB1 densities that are strongly affected by 35 neuropathology in 3×Tg-AD mice. At 2 months of age, there was no change in CB1 mRNA 36 and protein levels in 3×Tg-AD mice compared to Non-Tg mice in all brain areas analyzed. 37 However, at 6 and 12 months of age, CB1 mRNA levels were significantly higher in PFC, 38 DH, BLA and lower in VH in 3×Tg-AD mice compared to wild-type littermates. CB1 39 immunohistochemistry revealed that CB1 protein expression was unchanged in 3×Tg-AD at 2 40 and 6 months of age, while a significant decrease in CB1 receptor immunoreactivity was 41 detected in the BLA and DH of 12-month-old 3×Tg-AD mice, with no sign of alteration in 42 other brain areas. The altered CB1 levels appear, rather, to be age-and/or pathology- neurotransmitter systems are known to be affected by AD [2] . 60 The endocannabinoid system (ECS) has gained much attention as a new potential 61 pharmacotherapeutic target in various neurodegenerative diseases including AD. The CB1- control of neuronal excitability, and regulation of various forms of synaptic plasticity [3] . in CB1 expression and the development of AD neuropathology is still unclear. 70 Oddo and his colleagues developed a triple transgenic mouse model of AD (3×Tg-AD) 71 harbouring three mutant human genes PS1 M146V , APP Swe , and Tau P301L [9] . This model mimics 72 critical aspects of AD neuropathology observed in the human AD patients [10, 11] : it 73 progressively develops both plaques and tangles in AD relevant brain regions (mainly cortex, 74 hippocampus and amygdala); it exhibits early deficits in synaptic plasticity, including long-75 term potentiation; it shows selective loss of α7 neuronal nicotinic acetylcholine receptors [9, 76 12], severe deficits in glutamatergic neurotransmission and altered mitochondrial functions in 77 hippocampus and cortex [13] . 78 The aim of the present study was to evaluate whether brain CB1 expression is altered in 79 3×Tg-AD mice in comparison with wild type littermates (Non-Tg). Moreover, to investigate 80 whether the temporal and regional patterns of such possible alterations might overlap with 81 those of Aβ and tau pathology in this AD model, brain CB1 expression was analysed at 82 different ages [9] . As a consequence, by studying the temporal expression of CB1 in the wild 83 type littermates, our study has also allowed us to analyse the impact of aging on CB1 levels.
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Our analyses were conducted on both CB1 mRNA and CB1 protein levels in 3×Tg-AD and 
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Male 3×Tg-AD and Non-Tg mice aged 2-, 6-, and 12-months old were used in this study. Representative microphotographs of CB1 immunostaining are shown in Fig. 2A . Fig. 2B to Non-Tg mice (Fig.3 C, D) . Moreover, by performing a double immunofluorescence for 224 CB1 and Aβ (Fig.3 E, F 
